ANG-HM403-100μg / 询价
ANG-HM403-500μg / 询价
ANG-HM403-500μgx2 / 询价
Human ANGPTL3/Angiopoietin-like 3 Protein
Recombinant Human ANGPTL3/Angiopoietin-like 3 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Ser17-Lys219 [Accession | Q9Y5C1].
The protein has a predicted MW of 26.6 kDa. Due to glycosylation, the protein migrates to 30-38 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human ANGPTL3 on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.
Immobilized Human ANGPTL3, His Tag at 1 μg/ml (100μl/Well). Dose response curve for Anti-ANGPTL3 Antibody, hFc Tag with the EC50 of 42.3ng/ml determined by ELISA (QC Test).
Human LILRB2 captured on Protein A chip, can bind Human ANGPTL3, His Tag with an affinity constant of 17.6nM as determined in a SPR assay (Biacore T200).
ANGPTL3 is a secreted glycoprotein that is structurally related to the angiopoietins. Mature human ANGPTL3 contains an N-terminal coiled coil domain and a C‑terminal fibrinogen-like domain. ANGPTL3 is expressed in the liver from early in development through adulthood. Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake.
ANGPTL3; ANGPT5; ANG-5; Angiopoietin-5; FHBL2; ANL3; Angiopoietin-5; Angiopoietin-like Protein 3
(1) Oike Y , Akao M , Kubota Y , et al. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy[J]. Trends in Molecular Medicine, 2005, 11(10):473-479.
